| scholarly article | Q13442814 |
| P50 | author | Wolfgang Sippl | Q37836608 |
| P2093 | author name string | Cédric Atmanene | |
| Roman Lopez | |||
| Céline Reverdy | |||
| Vincent Collura | |||
| Frédéric Colland | |||
| Cécile Planquette | |||
| Jane Harpon | |||
| Susan Conrath | |||
| Valérie Vivat | |||
| Véronique Battaglia | |||
| P433 | issue | 4 | |
| P304 | page(s) | 467-477 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Chemistry and Biology | Q15758410 |
| P1476 | title | Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme | |
| P478 | volume | 19 |
| Q51462359 | A SUMO and ubiquitin code coordinates protein traffic at replication factories. |
| Q28395203 | A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance |
| Q93372543 | AMP Kinase Activation Attenuates Cardiac Remodeling in Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction; Lung Epithelial Progenitor Cells in Alveolar Regeneration; and Drug Discovery and Novel Therapies for Lung Cancer |
| Q47135501 | Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60. |
| Q39135148 | Activity-based probes for the ubiquitin conjugation-deconjugation machinery: new chemistries, new tools, and new insights |
| Q37718344 | CDDO-Me reveals USP7 as a novel target in ovarian cancer cells |
| Q40072442 | Cell Lysate-Based AlphaLISA Deubiquitinase Assay Platform for Identification of Small Molecule Inhibitors |
| Q38239700 | Cell death and deubiquitinases: perspectives in cancer |
| Q48194799 | Ceylonins G-I: spongian diterpenes from the marine sponge Spongia ceylonensis |
| Q38799376 | Chemical and semisynthetic approaches to study and target deubiquitinases. |
| Q59798588 | Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets |
| Q51632929 | Collective Synthesis and Biological Evaluation of Tryptophan-Based Dimeric Diketopiperazine Alkaloids. |
| Q26741797 | DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets |
| Q38336126 | DUBs, the regulation of cell identity and disease |
| Q38695071 | Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint |
| Q26823930 | Detection of ubiquitin-proteasome enzymatic activities in cells: application of activity-based probes to inhibitor development |
| Q38326071 | Deubiquitinases and the new therapeutic opportunities offered to cancer |
| Q35955141 | Deubiquitinases in cancer |
| Q98771233 | Deubiquitinating Enzyme: A Potential Secondary Checkpoint of Cancer Immunity |
| Q27003153 | Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1 |
| Q64098664 | Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities? |
| Q27026189 | Deubiquitinating enzymes as oncotargets |
| Q33836097 | Deubiquitinating enzymes as promising drug targets for infectious diseases |
| Q36744605 | Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake |
| Q38109871 | Deubiquitylating enzymes and DNA damage response pathways |
| Q48265884 | Deubiquitylating enzymes and drug discovery: emerging opportunities. |
| Q35044801 | Development of inhibitors in the ubiquitination cascade |
| Q48188572 | Discovery and characterization of highly potent and selective allosteric USP7 inhibitors |
| Q38196269 | Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives |
| Q26752823 | Drugging the undruggables: exploring the ubiquitin system for drug development |
| Q42291846 | Dual-utility NLS drives RNF169-dependent DNA damage responses. |
| Q59357734 | Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases |
| Q39171781 | Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication |
| Q50026815 | Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors |
| Q37387937 | HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma |
| Q24297641 | HAUSP, a novel deubiquitinase for Rb - MDM2 the critical regulator |
| Q26825542 | Histone H2B monoubiquitination: roles to play in human malignancy |
| Q58116151 | Identification and Characterization of USP7 Targets in Cancer Cells |
| Q47093588 | Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability |
| Q57840401 | Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells |
| Q47716589 | Inhibition of USP10 induces degradation of oncogenic FLT3. |
| Q57490982 | Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy |
| Q91923645 | Inhibition of p53 inhibitors: progress, challenges and perspectives |
| Q89519067 | Inhibition of the deubiquitinase USP10 induces degradation of SYK |
| Q37500984 | K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression |
| Q35148702 | Mechanism of action of thalassospiramides, a new class of calpain inhibitors |
| Q47098444 | Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents |
| Q28075457 | Modulation of the p53/MDM2 interplay by HAUSP inhibitors |
| Q47633676 | Molecular basis of USP7 inhibition by selective small-molecule inhibitors |
| Q38822748 | Monitoring Target Engagement of Deubiquitylating Enzymes Using Activity Probes: Past, Present, and Future |
| Q92529034 | Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease |
| Q34788381 | Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. |
| Q89581369 | Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth |
| Q92233313 | Profiling DUBs and Ubl-specific proteases with activity-based probes |
| Q38725385 | Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors |
| Q111285544 | Regulation of Cancer Metabolism by Deubiquitinating Enzymes: The Warburg Effect |
| Q38175783 | Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications |
| Q35232335 | Screening of DUB activity and specificity by MALDI-TOF mass spectrometry |
| Q38181181 | Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218). |
| Q83946194 | Selective inhibition of USP7 |
| Q90505741 | Small molecules that target the ubiquitin system |
| Q38181445 | Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system |
| Q36951802 | Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis |
| Q47619828 | Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. |
| Q89519064 | Targeting DUBs to degrade oncogenic proteins |
| Q38989377 | Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges. |
| Q52332504 | Targeting HAUSP in both p53 wildtype and p53-mutant tumors. |
| Q90349572 | Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs |
| Q92002855 | Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? |
| Q50130212 | Targeting deubiquitinase USP28 for cancer therapy |
| Q41678635 | Targeting the SUMO pathway for neuroprotection in brain ischaemia |
| Q38059739 | Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy |
| Q87038902 | Targeting the ubiquitin-proteasome system for cancer therapy |
| Q37496493 | The WD40-repeat protein-containing deubiquitinase complex: catalysis, regulation, and potential for therapeutic intervention |
| Q37517626 | The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics |
| Q64288182 | The role of ubiquitin-specific peptidases in cancer progression |
| Q90093670 | The role of ubiquitination in tumorigenesis and targeted drug discovery |
| Q92980454 | The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer |
| Q41056246 | Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones |
| Q98771728 | USP7 Is a Master Regulator of Genome Stability |
| Q47149840 | USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination |
| Q63246433 | USP7 Regulates Cytokinesis through FBXO38 and KIF20B |
| Q58749340 | USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation |
| Q37577477 | USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis |
| Q28834083 | USP7 is a SUMO deubiquitinase essential for DNA replication |
| Q38876635 | USP7 is essential for maintaining Rad18 stability and DNA damage tolerance. |
| Q46429336 | USP7 small-molecule inhibitors interfere with ubiquitin binding |
| Q89737230 | USP7 stabilizes EZH2 and enhances cancer malignant progression |
| Q64079043 | USP7: Novel Drug Target in Cancer Therapy |
| Q91936479 | USP7: Structure, substrate specificity, and inhibition |
| Q39214595 | Ubiquitin hydrolase UCH-L1 destabilizes mTOR complex 1 by antagonizing DDB1-CUL4-mediated ubiquitination of raptor |
| Q36509580 | Ubiquitin-Specific Proteases as Druggable Targets |
| Q84174712 | Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors |
| Q47100164 | Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. |
| Q38262067 | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
| Q39559509 | Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1. |
| Q64389021 | Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis |
| Q38265657 | Ubiquitination in disease pathogenesis and treatment |
| Q33977038 | Usp7 protects genomic stability by regulating Bub3. |
| Q61124626 | Usp7 regulates Hippo pathway through deubiquitinating the transcriptional coactivator Yorkie |
Search more.